Previous 10 | Next 10 |
BUILDING A SOLID BASE OF VAZALORE ® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021 GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP N...
SPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the po...
PLx Pharma Inc. (PLXP) Q4 2021 Results Earnings Conference Call March 11, 2022, 08:30 AM ET Company Participants Janet Barth - Vice President, Investor Relations and Corporate Communications Natasha Giordano - President and Chief Executive Officer Rita O'Connor - Chief Financial Officer and H...
PLx Pharma press release (NASDAQ:PLXP): Q4 GAAP EPS of -$0.73 misses by $0.02. Revenue of $1.59M misses by $0.46M. “The VAZALORE launch strategy is on track as planned. We are excited that VAZALORE is now the number three brand in the Aspirin Heart Health segment, within six months aft...
Momentum Building for Novel Vazalore ® Liquid-Filled Aspirin Capsules Total Net Sales of $8.2 Million in Last Five Months of 2021 Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales ...
SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the po...
SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the pot...
-- Female-Led Company Strives to Transform Standard of Care in Secondary Prevention of Heart Attack or Clot-Related Stroke with its Innovative New Aspirin Formulation VAZALORE ® -- SPARTA, N. J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLX...
SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potenti...
PLx Pharma (PLXP +10.7%) has gained more than a tenth in value after Raymond James upgraded the stock to Outperform from Market Perform, citing the recent weakness in its share price. The price target at $14 per share, implying a premium of ~70.5% to the last close, reflects a DCF model, ...
News, Short Squeeze, Breakout and More Instantly...
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE ® ,...
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to...
2023-04-11 06:00:00 ET 3 Tips for Finding Winning Penny Stocks in 2023 The potential for exponential growth has made penny stocks a favorite among investors seeking to capitalize on undervalued, up-and-coming companies. Penny stocks , typically defined as those trading below $5 per ...